 Sonova is still logging core growth in the mid-single-digits, but management has acknowledged some pressures from weaker high-margin sales and higher inputfulfillment costs. Macro pressures could lead to consumers trading down or postponing hearing aid purchases in 202324, but Sonovas latest offering Lumity should drive share gains. 